Sergio Fersino1, Stefano Arcangeli2, Barbara Alicja Jereczek-Fossa3, Rolando D'Angelillo4, Filippi Bertoni5, Giuseppe Roberto D'Agostino6, Luca Triggiani7, Renzo Corvò8, Stefano Maria Magrini7, Filippo Alongi9,10. 1. Radiation Oncology Department, Ospedale Sacro-Cuore Don Calabria, Via Don A. Sempreboni 5, 37024, Negrar, Verona, Italy. 2. Radiation Oncology Department, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy. 3. European Institute of Oncology, University of Milan, Milan, Italy. 4. Department of Radiation Oncology, Campus Biomedico University, Rome, Italy. 5. Genito-Urinary Group of AIRO - Italian Association for Radiation Oncology, Rome, Italy. 6. Radiosurgery and Radiotherapy Department, Istituto Clinico Humanitas Cancer Center and Research Hospital, Rozzano, Milan, Italy. 7. Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy. 8. Department of Radiation Oncology, IRCCS San Martino-IST National Cancer Research Institute and University, Genoa, Italy. 9. Radiation Oncology Department, Ospedale Sacro-Cuore Don Calabria, Via Don A. Sempreboni 5, 37024, Negrar, Verona, Italy. prof.filippoalongi@gmail.com. 10. University of Brescia, Brescia, Italy. prof.filippoalongi@gmail.com.
Abstract
AIMS: To investigate the role of Radiation Oncology in the management of genito-urinary (GU) cancer excluding prostate and penile cancer. METHODS: The questionnaire was focused on the evaluation of the degree of involvement of radiation oncologists in the work-up of bladder, renal cell carcinoma and testicular cancer (TC). RESULTS: Eighty-eight radiation oncologists completed the survey. The majority (85.4%) of participating radiation oncologists were senior consultants (> 5 years of experience). Sixty-four (73.6%) carried out a multidisciplinary tumor board discussion of GU cases, while 23 (26.4%) did not. Seventy-five percent of responders reported that, every year, visited < 50 GU patients (pts), 18.1% visited 50-100 pts and 6.9% visited > 100 pts. Bladder cancer, curative radiotherapy (RT) as part of trimodality approach was claimed to be adopted in less than 10 cases per year. Regarding renal cell carcinoma (RCC) patients, primary tumor directed RT was adopted only in 8 cases (9.4%) in at least 10 pts per year. Palliative RT was more frequent in RCC (48.2%) in over than 10 pts per year. In case of TC, the prescription of RT was limited (< 10 patients per year) due to the low incidence of disease and recent shift to surveillance as a first option in stage I seminoma. CONCLUSIONS: Our survey showed that radiation oncologists are rarely involved in the decision making strategy of GU cancer, despite many clinical trials support RT use. These patients probably deserve a more uniform approach based on updated, detailed and evidence-based recommendations.
AIMS: To investigate the role of Radiation Oncology in the management of genito-urinary (GU) cancer excluding prostate and penile cancer. METHODS: The questionnaire was focused on the evaluation of the degree of involvement of radiation oncologists in the work-up of bladder, renal cell carcinoma and testicular cancer (TC). RESULTS: Eighty-eight radiation oncologists completed the survey. The majority (85.4%) of participating radiation oncologists were senior consultants (> 5 years of experience). Sixty-four (73.6%) carried out a multidisciplinary tumor board discussion of GU cases, while 23 (26.4%) did not. Seventy-five percent of responders reported that, every year, visited < 50 GU patients (pts), 18.1% visited 50-100 pts and 6.9% visited > 100 pts. Bladder cancer, curative radiotherapy (RT) as part of trimodality approach was claimed to be adopted in less than 10 cases per year. Regarding renal cell carcinoma (RCC) patients, primary tumor directed RT was adopted only in 8 cases (9.4%) in at least 10 pts per year. Palliative RT was more frequent in RCC (48.2%) in over than 10 pts per year. In case of TC, the prescription of RT was limited (< 10 patients per year) due to the low incidence of disease and recent shift to surveillance as a first option in stage I seminoma. CONCLUSIONS: Our survey showed that radiation oncologists are rarely involved in the decision making strategy of GU cancer, despite many clinical trials support RT use. These patients probably deserve a more uniform approach based on updated, detailed and evidence-based recommendations.
Entities:
Keywords:
Cancer; Genito-urinary; Italian survey; Radiotherapy
Authors: M Walker; R C Doiron; S D French; D Feldman-Stewart; D R Siemens; W J Mackillop; C M Booth Journal: Clin Oncol (R Coll Radiol) Date: 2017-09-23 Impact factor: 4.126
Authors: Kyle Scarberry; Lee Ponsky; Edward Cherullo; William Larchian; Donald Bodner; Matthew Cooney; Rodney Ellis; Gregory Maclennan; Ben Johnson; William Tabayoyong; Robert Abouassaly Journal: Can Urol Assoc J Date: 2018-05-14 Impact factor: 1.862
Authors: Girish S Kulkarni; Thomas Hermanns; Yanliang Wei; Bimal Bhindi; Raj Satkunasivam; Paul Athanasopoulos; Peter J Bostrom; Cynthia Kuk; Kathy Li; Arnoud J Templeton; Srikala S Sridhar; Theodorus H van der Kwast; Peter Chung; Robert G Bristow; Michael Milosevic; Padraig Warde; Neil E Fleshner; Michael A S Jewett; Shaheena Bashir; Alexandre R Zlotta Journal: J Clin Oncol Date: 2017-04-14 Impact factor: 44.544